Literature DB >> 28965635

Monoclonal Antibodies Hypersensitivity: Prevalence and Management.

Rafael Bonamichi Santos1, Violeta Régnier Galvão2.   

Abstract

The use of monoclonal antibodies (mAbs) has become broader because of their recognized effectiveness in the treatment of autoimmune, neoplastic, and inflammatory diseases. Consequently, hypersensitivity reactions (HSR) secondary to mAbs are being reported more often, and each mAb-related HSR presents specific features. This article discusses the main biological agents and associated HSR, the clinical presentation of such reactions, and the role of tryptase and skin testing in the diagnosis. Rapid drug desensitization procedures to mAbs enable selected allergic patients to receive full therapeutic doses in a safe manner and are also discussed.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biological agents; Drug allergy; Immunoglobulin E; Monoclonal antibodies; Rapid drug desensitization; Skin test; Tryptase

Mesh：

Substances：

Year:  2017        PMID： 28965635     DOI： 10.1016/j.iac.2017.07.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  5 in total

1.  Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.

Authors:  Simbarashe Takuva; Shelly T Karuna; Michal Juraska; Erika Rudnicki; Srilatha Edupuganti; Maija Anderson; Robert De La Grecca; Martin R Gaudinski; Alice Sehurutshi; Catherine Orrell; Logashvari Naidoo; Javier Valencia; Larissa M Villela; Stephen R Walsh; Philip Andrew; Carissa Karg; April Randhawa; John Hural; Margarita M Gomez Lorenzo; David N Burns; Julie Ledgerwood; John R Mascola; Myron Cohen; Lawrence Corey; Kathy Mngadi; Nyaradzo M Mgodi
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771

2.  Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017.

Authors:  Matthew C Baker; Yingjie Weng; Robert Fairchild; Neera Ahuja; Nidhi Rohatgi
Journal:  JAMA Netw Open       Date:  2021-06-01

Review 3.  Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.

Authors:  Panagiotis F Christopoulos; Torleif T Gjølberg; Stig Krüger; Guttorm Haraldsen; Jan Terje Andersen; Eirik Sundlisæter
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

4.  Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.

Authors:  Victor M Villalobos; Gary Mo; Mark Agulnik; Seth M Pollack; Daniel A Rushing; Arun Singh; Brian A Van Tine; Rhian McNaughton; Rodney L Decker; Wei Zhang; Ashwin Shahir; Damien M Cronier
Journal:  Cancer Med       Date:  2019-12-10       Impact factor: 4.452

Review 5.  IgE Antibodies: From Structure to Function and Clinical Translation.

Authors:  Brian J Sutton; Anna M Davies; Heather J Bax; Sophia N Karagiannis
Journal:  Antibodies (Basel)       Date:  2019-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.